SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Shoenfeld, Y.
Right arrow Articles by Ziporen, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shoenfeld, Y.
Right arrow Articles by Ziporen, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review : Lessons from experimental APS models

Y. Shoenfeld

Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer

L. Ziporen

Sackler School of Medicine, Tel-Aviv University, Israel

Several animal models for antiphospholipid syndrome (APS) have been reported in the literature. These experimental models have contributed significantly in resolving enigmas in this multisystemic disease. We, and others have previously shown the pathogenicity of anticardiolipin (aCL) antibodies in pregnancy outcome. We have expanded our studies to show the pathogenicity of aCL antibodies in renal dysfunction and neurological and behavioral impairments in animals with experimental APS. Animals immunized with aCL or with the cofactor β2GPI developed clinical manifestations of APS, including fetal loss, thrombocytopenia and neurological and behavioral dysfunction, along with elevated levels of aPL antibodies. In another animal model, peripheral blood lymphocytes (PBLs) derived from APS patients could initiate APS manifestations with renal dysfunction in SCID mice. A unique in vivo model for thrombus formation was recently established to show the pathogenicity of aPL in thrombosis associated with APS. Histological evaluation of affected tissues derived from animals or from patients with APS have pointed to common mechanisms underlying APS, showing mainly thrombotic changes accompanied by mild inflammatory reaction.

Key Words: anti-cardiolipin • anti-phospholipid syndrome • autoimmunity • thrombocytopenia • β2-GPI

Lupus, Vol. 7, No. 2 suppl, S158-S161 (1998)
DOI: 10.1177/096120339800700234
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
A Katzav, J Chapman, and Y Shoenfeld
CNS dysfunction in the antiphospholipid syndrome
Lupus, December 1, 2003; 12(12): 903 - 907.
[Abstract] [PDF]

Home page
 LupusHome page
R L Brey, J Chapman, S R Levine, G Ruiz-Irastorza, R H. Derksen, M Khamashta, and Y Shoenfeld
Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002
Lupus, July 1, 2003; 12(7): 508 - 513.
[Abstract] [PDF]


Advertisement